Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.45 |
| ▸ | GUSB | P08236 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 3/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5352876 | 0.85 | SIRT2 (0.48) | SIRT2PARP10MAOBNR4A2 | |
| SCHEMBL6803013 | 0.84 | SIRT2 (0.49) | SIRT2PARP10KDM4ENPC1GAA | |
| SCHEMBL5358933 | 0.84 | PARP10 (0.51) | SIRT2PARP10MAOBNR4A2 | |
| SCHEMBL5355208 | 0.77 | SIRT2 (0.41) | SIRT2PARP10MAOB | |
| SCHEMBL15775940 | 0.75 | PARP10 (0.51) | SIRT2PARP10KDM4ENPC1GAA | |
| SCHEMBL15709261 | 0.74 | PARP15 (0.60) | SIRT2PARP10MAPTMAOB | |
| SCHEMBL10259006 | 0.73 | NR4A2 (0.54) | GUSBMAOBNR4A2 | |
| SCHEMBL4930554 | 0.72 | PARP10 (0.60) | SIRT2PARP10GAAMAPTRAB9A | |
| SCHEMBL7370244 | 0.71 | SPHK2 (0.47) | SIRT2PARP10MAOB | |
| SCHEMBL7907691 | 0.70 | MAOB (0.73) | SIRT2PARP10NPC1RAB9AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253194-B2 | Compounds and inhibitors of phospholipases | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-08-07 | — | — | US | disclosed |
| US-20040033995-A1 | Compounds and inhibitors of phospholipases | QUEENSLAND, THE UNIVERSITY OF (AU) | 2004-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040033995-A1 | Compounds and inhibitors of phospholipases | PLA2G4C, PLA2G4B, PLA2G4A | SIRT2 4701/4885PARP10 2145/4885GUSB 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.